Cholera Vaccines Industry Competitive Landscape and Industry Analysis 2030
The global cholera vaccine market was valued at USD 93.9 million in 2024 and is projected to reach USD 163.4 million by 2030, expanding at a healthy CAGR of 10.0% from 2025 to 2030. Cholera, caused by Vibrio cholerae, continues to be a major public health threat in endemic regions, particularly where access to clean water and proper sanitation is limited. Vaccines have become a critical preventive tool, and the availability of both oral and injectable formulations provides flexibility for use in different population groups and health settings.
Market growth is strongly supported by increasing awareness of cholera outbreaks in endemic regions and the proactive efforts of international health organizations, governments, and NGOs to control the disease. Strengthened vaccination campaigns and mass immunization drives have been launched to minimize outbreaks, while persistent research efforts and technological advancements are expected to enhance vaccine efficacy, improve shelf stability, and expand access to underserved populations.
The rise in international travel and migration has also amplified the need for cholera vaccination, particularly among travelers to endemic areas, humanitarian workers, and migrant populations. As governments and NGOs prioritize infectious disease prevention, vaccine demand has expanded significantly. At the same time, the increased innovation and availability of vaccines are helping improve outbreak management and reducing mortality in high-risk populations.
According to the Global Task Force on Cholera Control (GTFCC), cholera-related deaths are projected to decline by around 90% by 2030, primarily through the elimination of cases in 20 targeted countries. Beyond vaccination, preventive strategies such as improving access to safe water supplies, sanitation, and hygiene (WASH initiatives) are being actively implemented to reduce disease burden. Furthermore, voluntary intellectual property (IP) licensing and technology transfer agreements are playing a pivotal role in scaling up the production and equitable distribution of oral cholera vaccines (OCVs), ensuring broader accessibility in low- and middle-income countries.
Key Market Trends & Insights:
- Regional Insights: North America dominated the global cholera vaccines market, accounting for a 37.6% revenue share in 2024, largely due to the presence of major pharmaceutical companies, a well-established healthcare infrastructure, and a high number of outbound travelers seeking preventive vaccinations. Within North America, Canada is expected to grow at the fastest CAGR of 9.9% in 2024, supported by increasing awareness, government vaccination programs, and growing travel immunization demand.
- Type Insights: The killed oral O1 and O139 segment held the largest market share of 60.0% in 2024 and is projected to grow at the fastest CAGR of 11.5% during the forecast period. This dominance is attributed to their proven safety, effectiveness in preventing outbreaks, and widespread use in endemic countries.
- Product Insights: Dukoral led the market with a 32.5% revenue share in 2024, mainly driven by its popularity among international travelers to endemic regions. Vaxchora is expected to grow at the fastest CAGR of 14.1%, fueled by its approval in multiple markets, single-dose oral formulation, and increasing adoption among both travelers and populations in cholera-prone regions.
- Distribution Channel Insights: Hospital pharmacies dominated the distribution channel segment, capturing a 45.5% revenue share in 2024, as hospitals serve as primary points of care for vaccination programs and travel medicine.
Order a free sample PDF of the Cholera Vaccines Market Intelligence Study, published by Grand View Research.
Market Size & Forecast:
- 2024 Market Size: USD 93.9 Million
- 2030 Projected Market Size: USD 163.4 Million
- CAGR (2025-2030): 10.0%
- North America: Largest market in 2024
Key Companies & Market Share Insights:
- The global cholera vaccine market is moderately consolidated, with several leading players actively contributing to research, production, and distribution. Key companies include Valneva SE, Sanofi S.A., and Emergent BioSolutions Inc., among others. These companies pursue strategies such as new product launches, collaborations with international health bodies, expansion into emerging markets, and digital health integration to improve vaccine access and adherence.
- Valneva SE specializes in the development, manufacturing, and commercialization of prophylactic vaccines against infectious diseases. Its flagship product Dukoral is widely used for active immunization, especially among travelers to endemic regions. Valneva continues to improve Dukoral’s formulation and expand its accessibility to a broader global population.
- Sanofi S.A. develops a diverse portfolio of pharmaceutical and vaccine products, including Vaxchora, which is administered to adults and children aged two years and above for cholera prevention. The company has been expanding vaccine accessibility and affordability, particularly in endemic areas, while collaborating with global organizations such as the World Health Organization (WHO) to strengthen supply chains and ensure wider vaccine distribution.
- Emergent BioSolutions Inc. and other players are investing in collaborative research, technological innovation, and production scalability to meet the growing global demand for oral cholera vaccines. These efforts are further enhanced by partnerships with governments and NGOs, reinforcing vaccination programs in high-risk areas.
Explore our latest blogs: Global Industry Herald
Conclusion:
The cholera vaccine market is expected to witness strong growth, driven by rising awareness in endemic regions, expanding international travel, and active support from global health organizations and governments. While oral killed vaccines such as Dukoral currently dominate the market, newer options like Vaxchora are gaining traction due to their convenience and effectiveness. With preventive initiatives, voluntary licensing, and technology transfer supporting wider vaccine distribution, the market is set to expand further, positioning cholera vaccination as a key tool in global infectious disease prevention strategies.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Games
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness
- IT, Cloud, Software and Technology
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian